Clinical Trial Search

Primary: Degree of Improvement in Erythematotelangiectatic Rosacea and Papulopustular Rosacea — 2.114; 2.088 score on a scale

Primary: Clinical Erythema Assessment (CEA) Score At 6-Month Post-Baseline — 1.6; 2.4 score on a scale

Primary: Responder — 16.7 percentage of responders

Primary: Improvement of the Inflammatory Lesions (Papules, Pustules, Nodules), Erythema, and Telangiectasia of Rosacea as Assessed by the Investigator's Global Assessment (IGA)…

Primary: Change From Baseline in the Total Number of Papulopustular Lesions at Week 12 — -0.2 papule count — p=0.98

Primary: Proportion of Subjects With Composite Success — 60; 58; 23 Participants

Primary: Long Term Safety & Efficacy of CD07805/47 Gel 0.5% in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea. — -1.5; -1.4; -1.5; -1.7 scores on a scale

Primary: Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 5; 0 Participants

Primary: Percentage of Participants With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment (SSA) — 13.3; 20.5…

Primary: Composite Success — 36; 13; 36; 13 participants — p=<0.001

Primary: Composite Success — 40; 14; 39; 12 participants — p=<0.001

Primary: Response Rate for Achieving a 2 Grade Improvement on Clinician's Erythema Assessment (CEA) and Patient Self Assessment (PSA) Over 12 Hours After Dosing. — 17; 10; 7; 4…

Primary: Composite Success Assessment (CEA) and Patient Self Assessment(PSA). — 32; 48; 33; 46 participants

Primary: Percentage of Patients With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point…

Primary: Percentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment for…

Primary: Composite Success — 16; 10; 10; 2 participants — p=<0.001

Primary: Percentage of Responders With at Least a 2-Grade Decrease From Baseline in Both Clinician Erythema Assessment (CEA) and Subject's Self Assessment (SSA) at Day 1 — 15.6…

Primary: Total Number of Flushes for Each 2-week Period — 15.3; 16.3 Flushes count — p=0.7420

Primary: Adherence - MEMs Cap — 21; 6; 15; 12 Participants

Primary: Co-primary Endpoint: Change From Baseline in Number of Rosacea Inflammatory Lesions — -10.0; -6.7; -9.2 lesions (rosacea inflammatory)

Primary: Percentage of Participants With Treatment-Related Adverse Events — 8.2 percentage of participants

Primary: IGA of Improvement — 3.1; 3.5 units on a scale

Primary: Primary: Percentage of Treatment Success on Day 7 — 9.95; 10.36; 0 percentage of participants — p=<0.0001

Primary: Percentage of Participants Who Are Very Satisfied/Satisfied/Somewhat Satisfied With the Overall Study Treatment — 69.6; 40.4 Percentage of participants — p== 0.0065

Primary: Facial Erythema — 6.6; 6 score on a scale

Primary: Erythema Severity — 44.53 Erythema percent improvement

Primary: Success Rate — 40.1; 18.8 Percentage of participants — p=<0.001

Primary: Success Rate — 38.4; 11.6 Percentage of participants — p=<0.001

Primary: Reduction of Flushing, Erythema, Telangiectasia, Papules, and Pustules — 1; 1.92 score on a scale

Primary: Mean Percent Change From Baseline in the Inflammatory (Papules and Pustules) Lesion Count — 65.47; 67.89; 55.51 percentage of lesion reduction